MenQuadfi, Sanofi Pasteur's tetravalent meningococcal vaccine, is expected to be released soon.

According to the pharmaceutical industry on the 7th, Sanofi Pasteur completed receiving product licenses from the Ministry of Food and Drug Safety, including clinical trials of MenQuadfi, a vaccine for meningococcal (A, C, Y, W) to prevent invasive meningococcal infections in children and adults over the age of 2.

MenQuadfi is designed to induce high immune responses for four serum groups across a wide range of ages from 2 to 56 and was FDA-approved as the first and only tetravalent meningococcal vaccine in the United States using tetanus toxoid as a protein carrier in April 2020. FDA approval